Accelerating Complex Biomarkers, Novel & Multimodal Endpoints to Fuel Drug-Diagnostic Innovations from Bench-to-Bedside for Global Precision Medicine Access
As regulatory headwinds turn to tailwinds, precision medicine is shifting into a new gear.
Evolving FDA approaches to LDTs and 510(k) pathways are removing long-standing friction, coordinated Rx-Dx launches are gaining pace, ctDNA and MRD are advancing as clinically meaningful endpoints, and reimbursement expansion is improving access to high-value genomic testing. At the same time, innovation in multiplex assays, multi-omics platforms, liquid biopsy, digital pathology, spatial biology, and AI-powered diagnostics, are rapidly reshaping the IVD landscape.
Fueled by $60B+ in diagnostic deal-making and strategic partnerships, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns as the industry's esteemed end-to-end precision medicine forum. Convening 850+ senior leaders from biopharma, diagnostic, regulatory, healthcare, testing labs and multimodal communities, with expertise spanning the full value chain, gain the insights, partnerships and insider know-how to prime your team for continued clinical and commercial success.
With the race to bring scalable, accessible drug-diagnostic programs from bench-to-bedside heating up, join us in harnessing the speed, scale, and growing complexity of innovation happening in next-generation IVD platforms, multimodal data, and CDx development.
A Snapshot of the World-Class Speaker Faculty
Expect to Connect With
About the World Biomarkers & Diagnostics Event Series
The World Biomarkers & Diagnostics Event Series continues to serve as the trusted home of the global precision medicine community. Bringing leaders across biopharma, diagnostics, technology, testing laboratories, and healthcare together to advance biomarker-driven drug development and diagnostic innovation.
Meaningful connections define our community. That is why we have created a trusted environment for the industry to share real-world experiences, benchmark approaches, exchange emerging evidence, and forge collaborations that drive progress across the drug and diagnostic co-development lifecycle.
We are united in the shared industry belief that biomarkers and diagnostics are fundamental to the future of precision medicine. As testing becomes increasingly critical to identifying the right patients and enabling more effective therapies, our mission remains simple; to ensure the right treatment reaches the right patient, at the right time.
Join the industry's most valued biomarker and diagnostics event and be part of the conversations shaping the very future of precision medicine.